向MTHFD2改变了代谢平衡,并与博特佐米布协同,以抑制多发性骨髓瘤
Mingyuan Jia1, Ze Fu1, Chenjing Ye2
1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
甲基酸脱酶2 (MTHFD2) 在多发性骨髓瘤 (MM) 中过度表达,其向显示出抗癌作用. 抑制MTHFD2会破坏MM细胞的新陈代谢,并与博特佐米布协同,以改善治疗结果.
科学领域:
- 在瘤学瘤学.
- 代谢途径 代谢途径
- 血液性恶性瘤 血液性恶性瘤
背景情况:
- 多发性骨髓瘤 (MM) 尽管有治疗进展,但仍然无法治愈.
- 耐药性需要新的治疗点.
- 甲基酸酸脱酶2 (MTHFD2) 在MM中的作用尚不清楚.
研究的目的:
- 研究MM中MTHFD2的生物功能和机制.
- 评估MTHFD2作为MM的潜在治疗标.
- 探索MTHFD2和博尔特佐米布敏感性之间的关系.
主要方法:
- 在MM患者样本中分析MTHFD2表达.
- 针对MTHFD的体外和体内研究2.2.
- 评估代谢途径 (糖解,线粒体呼吸) 和未折叠蛋白质反应 (UPR).
- 与博特佐米布的联合研究.
主要成果:
- 在MM中,MTHFD2过度表达,与预后不佳相关.
- 准MTHFD2在体外和体内都表现出了抗MM作用.
- 抑制MTHFD2会影响糖解和线粒体呼吸.
- 通过减少XBP1s表达,MTHFD2的淘汰影响了UPR.
- MTHFD2水平预测了博特佐米布的敏感性.
- 针对MM的MTHFD2向与博尔特佐米布协同作用.
结论:
- MTHFD2是多发性骨髓瘤的一个有前途的治疗点.
- 准MTHFD2会破坏MM细胞中的代谢平衡.
- 抑制MTHFD2与博尔特佐米布有协同作用,为MM提供了潜在的组合疗法.
更多相关视频
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
10:41Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
Published on: March 29, 2017
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Treatment Resistant Cancers
